BriaCell Therapeutics Corp

BCT

Company Profile

  • Business description

    BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

  • Contact

    235-15th Street
    Suite 300, 3rd Floor, Bellevue Centre
    West Vancouver
    VancouverBCV7T 2X1
    CAN

    T: +1 888 485-6340

    https://www.briacell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 July 2025

    Employees

    12

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,912.35111.471.43%
DAX 4024,267.46297.101.24%
Dow JONES (US)44,837.5664.36-0.14%
FTSE 1009,135.8054.360.60%
HKSE25,524.4537.68-0.15%
NASDAQ21,178.5870.270.33%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,936.4125.670.20%
S&P 5006,389.771.130.02%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers